Biocon Ltd on 28 March 2016 announced that the Ministry of Health, Labour and Welfare (MHLW) of Japan approved its biosimilar Insulin Glargine.
•    The approval for Insulin Glargine was obtained post successful completion of initial development by Biocon and local Phase III Clinical Studies in over 250 Type 1 Diabetes patients by its partner FUJIFILM Pharma Co. Ltd (FFP) in Japan.
•    The product will be available in Japan in 2017 in the form of disposable pen with 3 ml of 100IU Insulin Glargine. 
•    At present, it is available in India with the brand name Basalog One.
•    With this launch, the company is also aiming to capture a significant share of the Japanese Glargine market of 144 million US dollars.
•    It is the second largest market outside of North America and Europe and is largely dominated by disposable pens.
•    It is India's largest and fully-integrated, innovation-led biopharmaceutical company.
•    The Bengaluru-based company serves its customers in over 100 countries.
•    Its products are focused on chronic diseases like autoimmune, diabetes and cancer.
•    It has successfully developed and taken a range of novel biologics, biosimilars, differentiated small molecules and affordable recombinant human insulin and analogs from 'Lab to Market'.
•    It has a rich pipeline of biosimilars and novel biologics at various stages of development including high potential oral insulin.